Deborah Mortensen

Deborah Mortensen has over 30 years of work experience in the pharmaceutical industry. Deborah is currently the Director of Medical Writing at QED Therapeutics since January 2021. Prior to that, from 2019 to 2021, they worked as an Associate Director of Medical Writing at Myovant Sciences.

Deborah also has extensive experience at Genentech, where they held various roles. From 2014 to 2019, they were a Documentation Team Leader, responsible for leading a global team of medical writers and providing strategic guidance in the late-stage CNS and ophthalmology therapeutic areas. Before that, from 2014 to 2017, they served as a Principal Medical Writer and Project and Filing Lead, overseeing the writing and submission of regulatory documents for clinical development programs and drug license applications.

At Genentech, Deborah started their career in 1988 and held positions of increasing responsibility. As a Principal Scientific Researcher from 2004 to 2014, they drove strategies for early-stage drug development through IND and beyond, with a primary focus on preclinical and translational pharmacology/pharmacokinetics. Prior to that, they worked as a Senior Scientific Researcher from 1997 to 2004 and as a Research Associate from 1988 to 1997.

Throughout their career, Deborah Mortensen has gained expertise in medical writing, project management, global regulatory filings, clinical documentation, and early-stage drug development across multiple therapeutic areas.

Deborah Mortensen has a BA degree in Management from Saint Mary's College of California. Deborah also holds an AS degree in Biological Sciences from Foothill College. The exact years of their education are not provided.